免疫检查点抑制剂相关性肝损伤  

Immunological checkpoint inhibitor-associated liver injury

作　　者：于越 刘宝刚[1] YU Yue;LIU Baogang(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2021年第17期3117-3120,共4页Journal of Modern Oncology

摘　　要：近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已成为恶性肿瘤治疗的关键药物之一。它与传统的放化疗机制完全不同,它主要是针对人体的免疫系统发挥抗肿瘤作用,它是目前新型的治疗方法之一。但是,同样它也会引起相应的不良反应。本文旨在讨论ICIs对肝脏的不良反应和治疗效果。同时,因其发病机制与自身免疫性疾病相近,本文还进一步探讨了它们之间的异同。In recent years,immune checkpoint inhibitors(ICIs)have become one of the key drugs for the treatment of malignant tumors.It is completely different from the traditional radiotherapy and chemotherapy mechanism.It mainly targets the human immune system and exerts anti-tumor effect.It is one of the new treatment methods.However,it also causes corresponding side effects.This article aims to discuss the adverse reactions and treatment of ICIs in the liver.At the same time,because its pathogenesis is similar to autoimmune diseases,this paper further explores the similarities and differences between them.

关 键 词：免疫检查点抑制剂 肝损伤 肿瘤 

分 类 号：R735.7[医药卫生—肿瘤]